MERIT is an innovative clinical endpoint expert providing attentive expertise in our therapeutic areas. We partner with CROs, pharma, and biotech companies to deliver reliable endpoint services in global clinical trials. With the acquisition of OSOD, MERIT now offers preclinical research services, enabling a seamless transition from preclinical to clinical phases of drug development. Together our work advances and accelerates the improvement of therapeutic options for patients worldwide. We have a proven track record providing endpoint expertise to 13 of the top 20 global pharmaceutical companies. We prioritize a collaborative, partnership-driven approach for all projects with scalable solutions and personalized attention. If you’re looking for a partner that will bring dedication and expertise to your clinical trial, consider MERIT. Show more Show less
$1.1M sweet spot round size
2012
$1.1M
from investors over 1 rounds
MERIT CRO raised $1.1M on August 20, 2023